Showing 421-430 of 19172 results for "".
Breaking Down Biosimilar Insulins: A Look at the Regulatory Process and Impacts
https://reachmd.com/programs/diabetes-discourse/breaking-down-biosimilar-insulins-a-look-at-the-regulatory-process-and-impacts/16062/How might biosimilar insulins transform the way we prescribe treatment for our patients with type 1 and type 2 diabetes?Strategies for Addressing Diabetes Stigma and Discrimination
https://reachmd.com/programs/diabetes-discourse/strategies-for-addressing-diabetes-stigma-and-discrimination/16367/Tune in to learn about the stigma and discrimination patients with diabetes can face and how we as healthcare providers can reduce that burden.Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression
https://reachmd.com/programs/focus-on-diabetes/inhaled-corticosteroids-and-the-risks-of-diabetes-onset-and-progression/6093/Systemic corticosteroids increase the risk of diabetes, but what about in patients who take high-dose inhaled corticosteroids? How do we best manage the risk-benefit equation in patients with chronic obstructive pulmonary disease (or COPD)? Dr. Christopher Slatore, assistant professor in the divisioEvaluating Early Signs of Diabetes: A Look at Asymptomatic Patients
https://reachmd.com/programs/diabetes-discourse/evaluating-early-signs-of-diabetes-a-look-at-asymptomatic-patients/12587/How can approach identifying diabetes early if patients appear asymptomatic in the beginning?Underrecognition of Diabetes in Cardiology Practice
https://reachmd.com/programs/lipid-luminations/underrecognition-of-diabetes-in-cardiology-practice/6779/Joining Dr. Alan Brown is Revathi Balakrishnan, MD, MPH, a general cardiology fellow at NYU and winner of the NLA Young Investigator Competition. Dr. Balakrishnan's research, titled "Prevalence of unrecognized prediabetes, diabetes and metabolic syndrome in patients undergoing non-urgent PCI," foundI Just Received an Offer from a Private Equity Firm. What Should I Do Now?
https://modernaesthetics.com/topics/practice-development/i-just-received-an-offer-from-a-private-equity-firm-what-should-i-do-now/35206/Why you need a knowledgeable transaction advisor when considering a private equity deal.Midwest Lipid Association Conference Series I
https://reachmd.com/programs/lipid-luminations/midwest-lipid-association-conference-series-i/1927/Tune in to hear Dr. Larry Kaskel on site at the Lipid Conference. In this first of a two part series, Dr. Kaskel catches top thought leaders at the conference to get their candid remarks on important lipid topics. Brought to you by:The Relationship Between Diabetes and Periodontal Disease
https://reachmd.com/programs/diabetes-discourse/the-relationship-between-diabetes-and-periodontal-disease/5678/Periodontitis is considered the sixth major diabetes-related complication. What do healthcare professionals need to know to help their patients with diabetes? Join guest host and registered dietitian Janice Baker and her guest, dentist in San Diego, California, Dr. Timothy Garofolo, as they discussEmerging Patterns in Diabetes Management
https://reachmd.com/programs/focus-on-pharmacy/emerging-patterns-in-diabetes-management/3532/It is estimated that a diabetes-related death occurs around the world once every ten seconds. In that same ten-second interval, two citizens of the world develop the disease. As general global trends persist toward a decrease in activity and an increase in food consumption, what will we see as partNew Drug for Diabetic Patients in Phase 2 Trials
https://reachmd.com/programs/clinicians-roundtable/new-drug-for-diabetic-patients-in-phase-2-trials/125/Dr. Berkowitz, President and CEO of Alteon, Inc. discusses a new drug that they are developing for diabetic patients.